123 related articles for article (PubMed ID: 24500783)
1. The antiprogestins mifepristone and onapristone reduce cell proliferation in the canine mammary carcinoma cell line CMT-U27.
Guil-Luna S; Hellmén E; Sánchez-Céspedes R; Millán Y; Martín de las Mulas J
Histol Histopathol; 2014 Jul; 29(7):949-55. PubMed ID: 24500783
[TBL] [Abstract][Full Text] [Related]
2. Onapristone (ZK299) and mifepristone (RU486) regulate the messenger RNA and protein expression levels of the progesterone receptor isoforms A and B in the bovine endometrium.
Rekawiecki R; Kowalik MK; Kotwica J
Theriogenology; 2015 Aug; 84(3):348-57. PubMed ID: 25976976
[TBL] [Abstract][Full Text] [Related]
3. Modulation of oestrogenic effects by progesterone antagonists in the rat uterus.
Chwalisz K; Stöckemann K; Fritzemeier KH; Fuhrmann U
Hum Reprod Update; 1998; 4(5):570-83. PubMed ID: 10027611
[TBL] [Abstract][Full Text] [Related]
4. The antiprogestins RU486 and ZK98299 affect follicle-stimulating hormone secretion differentially on estrus, but not on proestrus.
Ringstrom SJ; Szabo M; Kilen SM; Saberi S; Knox KL; Schwartz NB
Endocrinology; 1997 Jun; 138(6):2286-90. PubMed ID: 9165013
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness of three antiprogestins alone and in combination with anordiol in terminating pregnancy in the rat.
Dao B; Vanage G; Li XJ; Bardin CW; Koide SS
Contraception; 1997 Jan; 55(1):35-40. PubMed ID: 9013059
[TBL] [Abstract][Full Text] [Related]
6. Progesterone receptor involvement in independent tumor growth in MPA-induced murine mammary adenocarcinomas.
Montecchia MF; Lamb C; Molinolo AA; Luthy IA; Pazos P; Charreau E; Vanzulli S; Lanari C
J Steroid Biochem Mol Biol; 1999 Jan; 68(1-2):11-21. PubMed ID: 10215033
[TBL] [Abstract][Full Text] [Related]
7. Synergistic growth inhibitory effect of deracoxib with doxorubicin against a canine mammary tumor cell line, CMT-U27.
Bakirel T; Alkan FÜ; Üstüner O; Çinar S; Yildirim F; Erten G; Bakirel U
J Vet Med Sci; 2016 May; 78(4):657-68. PubMed ID: 26822118
[TBL] [Abstract][Full Text] [Related]
8. Antiprogestins suppress basal and activin-stimulated follicle-stimulating hormone secretion in an estrogen-dependent manner.
Szabo M; Kilen SM; Saberi S; Ringstrom SJ; Schwartz NB
Endocrinology; 1998 May; 139(5):2223-8. PubMed ID: 9564826
[TBL] [Abstract][Full Text] [Related]
9. Growth hormone receptor (GHR) RNAi decreases proliferation and enhances apoptosis in CMT-U27 canine mammary carcinoma cell line.
Pawłowski KM; Popielarz D; Szyszko K; Gajewska M; Motyl T; Król M
Vet Comp Oncol; 2012 Mar; 10(1):2-15. PubMed ID: 22235976
[TBL] [Abstract][Full Text] [Related]
10. Anti-cancer effect of palmatine through inhibition of the PI3K/AKT pathway in canine mammary gland tumor CMT-U27 cells.
Yoo MJ; Choi J; Jang YJ; Park SY; Seol JW
BMC Vet Res; 2023 Oct; 19(1):223. PubMed ID: 37880653
[TBL] [Abstract][Full Text] [Related]
11. Progesterone receptor isoform A may regulate the effects of neoadjuvant aglepristone in canine mammary carcinoma.
Guil-Luna S; Stenvang J; Brünner N; De Andrés FJ; Rollón E; Domingo V; Sánchez-Céspedes R; Millán Y; Martín de Las Mulas J
BMC Vet Res; 2014 Dec; 10():296. PubMed ID: 25515784
[TBL] [Abstract][Full Text] [Related]
12. Induction of the angiogenic factor VEGF in the uterus by the antiprogestin onapristone.
Hyder SM; Chiappetta C; Stancel GM
Cancer Lett; 2000 Aug; 156(1):101-7. PubMed ID: 10840165
[TBL] [Abstract][Full Text] [Related]
13. Demonstration of mixed properties of RU486 in progesterone receptor (PR)-transfected MDA-MB-231 cells: a model for studying the functions of progesterone analogues.
Lin VC; Aw SE; Ng EH; Ng EH; Tan MG
Br J Cancer; 2001 Dec; 85(12):1978-86. PubMed ID: 11747343
[TBL] [Abstract][Full Text] [Related]
14. Androgen-like and anti-androgen-like effects of antiprogestins in human mammary cancer cells.
Hackenberg R; Hannig K; Beck S; Schmidt-Rhode P; Scholz A; Schulz KD
Eur J Cancer; 1996 Apr; 32A(4):696-701. PubMed ID: 8695275
[TBL] [Abstract][Full Text] [Related]
15. The antagonists RU486 and ZK98299 stimulate progesterone receptor binding to deoxyribonucleic acid in vitro and in vivo, but have distinct effects on receptor conformation.
Gass EK; Leonhardt SA; Nordeen SK; Edwards DP
Endocrinology; 1998 Apr; 139(4):1905-19. PubMed ID: 9528977
[TBL] [Abstract][Full Text] [Related]
16. Transcriptomic profile of two canine mammary cancer cell lines with different proliferative and anti-apoptotic potential.
Krol M; Pawlowski KM; Skierski J; Rao NA; Hellmen E; Mol JA; Motyl T
J Physiol Pharmacol; 2009 May; 60 Suppl 1():95-106. PubMed ID: 19609018
[TBL] [Abstract][Full Text] [Related]
17. Induction of TGF-beta by an antiprogestin in the human breast cancer cell line T-47D.
Dannecker C; Possinger K; Classen S
Ann Oncol; 1996 Apr; 7(4):391-5. PubMed ID: 8805931
[TBL] [Abstract][Full Text] [Related]
18. Two types of antiprogestins identified by their differential action in transcriptionally active extracts from T47D cells.
Klein-Hitpass L; Cato AC; Henderson D; Ryffel GU
Nucleic Acids Res; 1991 Mar; 19(6):1227-34. PubMed ID: 2030942
[TBL] [Abstract][Full Text] [Related]
19. Effects of the progesterone antagonists onapristone (ZK 98 299) and ZK 136 799 on surgically induced endometriosis in intact rats.
Stoeckemann K; Hegele-Hartung C; Chwalisz K
Hum Reprod; 1995 Dec; 10(12):3264-71. PubMed ID: 8822456
[TBL] [Abstract][Full Text] [Related]
20. Aglepristone decreases proliferation in progesterone receptor-positive canine mammary carcinomas.
Guil-Luna S; Sánchez-Céspedes R; Millán Y; De Andrés FJ; Rollón E; Domingo V; Guscetti F; Martín de Las Mulas J
J Vet Intern Med; 2011; 25(3):518-23. PubMed ID: 21488964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
